Received May 19, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 9c75y | — |
patient received the first Shingrix shot in June of 2025 and received the second shot yesterday; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) (batch number 9c75y, expiry date 02-MAY-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose in JUN-2025). On 11-MAY-2026, the patient received the 2nd dose of Shingrix. On 11-MAY-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient received the first Shingrix shot in June of 2025 and received the second shot yesterday). The outcome of the drug dose administration interval too long was not applicable.